Efficacy of hypomethylating agents in therapy-related myelodysplastic syndromes

Virginia M. Klimek, Emily K. Dolezal, Michael T. Tees, Sean M. Devlin, Karen Stein, Alejandro Romero, Stephen D Nimer

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

We retrospectively assessed morphologic and cytogenetic responses to 5-azacytidine and decitabine in a cohort of 42 adult therapy-related myelodysplastic syndromes (tMDS) patients treated at Memorial Sloan-Kettering Cancer Center and in 2 industry-sponsored decitabine trials (D0007 and DACO-020). The overall response rate (complete remission. +. marrow CR. +. hematologic improvement) was 38%, including 6 patients with complete remission (14%), 6 with marrow CR with or without hematologic improvement (14%), and 4 with hematologic improvement alone (10%). We conclude that DNA methyltransferase inhibitors showed activity in tMDS that is roughly comparable to that seen in de novo MDS.

Original languageEnglish
Pages (from-to)1093-1097
Number of pages5
JournalLeukemia Research
Volume36
Issue number9
DOIs
StatePublished - Sep 1 2012
Externally publishedYes

Fingerprint

decitabine
Myelodysplastic Syndromes
Bone Marrow
Azacitidine
Methyltransferases
Cytogenetics
Industry
DNA
Therapeutics
Neoplasms

Keywords

  • 5-Azacytidine
  • Decitabine
  • Leukemia
  • Therapy-related cancer

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology

Cite this

Klimek, V. M., Dolezal, E. K., Tees, M. T., Devlin, S. M., Stein, K., Romero, A., & Nimer, S. D. (2012). Efficacy of hypomethylating agents in therapy-related myelodysplastic syndromes. Leukemia Research, 36(9), 1093-1097. https://doi.org/10.1016/j.leukres.2012.04.025

Efficacy of hypomethylating agents in therapy-related myelodysplastic syndromes. / Klimek, Virginia M.; Dolezal, Emily K.; Tees, Michael T.; Devlin, Sean M.; Stein, Karen; Romero, Alejandro; Nimer, Stephen D.

In: Leukemia Research, Vol. 36, No. 9, 01.09.2012, p. 1093-1097.

Research output: Contribution to journalArticle

Klimek, VM, Dolezal, EK, Tees, MT, Devlin, SM, Stein, K, Romero, A & Nimer, SD 2012, 'Efficacy of hypomethylating agents in therapy-related myelodysplastic syndromes', Leukemia Research, vol. 36, no. 9, pp. 1093-1097. https://doi.org/10.1016/j.leukres.2012.04.025
Klimek VM, Dolezal EK, Tees MT, Devlin SM, Stein K, Romero A et al. Efficacy of hypomethylating agents in therapy-related myelodysplastic syndromes. Leukemia Research. 2012 Sep 1;36(9):1093-1097. https://doi.org/10.1016/j.leukres.2012.04.025
Klimek, Virginia M. ; Dolezal, Emily K. ; Tees, Michael T. ; Devlin, Sean M. ; Stein, Karen ; Romero, Alejandro ; Nimer, Stephen D. / Efficacy of hypomethylating agents in therapy-related myelodysplastic syndromes. In: Leukemia Research. 2012 ; Vol. 36, No. 9. pp. 1093-1097.
@article{35543150afb44488b91af3d6d99a618c,
title = "Efficacy of hypomethylating agents in therapy-related myelodysplastic syndromes",
abstract = "We retrospectively assessed morphologic and cytogenetic responses to 5-azacytidine and decitabine in a cohort of 42 adult therapy-related myelodysplastic syndromes (tMDS) patients treated at Memorial Sloan-Kettering Cancer Center and in 2 industry-sponsored decitabine trials (D0007 and DACO-020). The overall response rate (complete remission. +. marrow CR. +. hematologic improvement) was 38{\%}, including 6 patients with complete remission (14{\%}), 6 with marrow CR with or without hematologic improvement (14{\%}), and 4 with hematologic improvement alone (10{\%}). We conclude that DNA methyltransferase inhibitors showed activity in tMDS that is roughly comparable to that seen in de novo MDS.",
keywords = "5-Azacytidine, Decitabine, Leukemia, Therapy-related cancer",
author = "Klimek, {Virginia M.} and Dolezal, {Emily K.} and Tees, {Michael T.} and Devlin, {Sean M.} and Karen Stein and Alejandro Romero and Nimer, {Stephen D}",
year = "2012",
month = "9",
day = "1",
doi = "10.1016/j.leukres.2012.04.025",
language = "English",
volume = "36",
pages = "1093--1097",
journal = "Leukemia Research",
issn = "0145-2126",
publisher = "Elsevier Limited",
number = "9",

}

TY - JOUR

T1 - Efficacy of hypomethylating agents in therapy-related myelodysplastic syndromes

AU - Klimek, Virginia M.

AU - Dolezal, Emily K.

AU - Tees, Michael T.

AU - Devlin, Sean M.

AU - Stein, Karen

AU - Romero, Alejandro

AU - Nimer, Stephen D

PY - 2012/9/1

Y1 - 2012/9/1

N2 - We retrospectively assessed morphologic and cytogenetic responses to 5-azacytidine and decitabine in a cohort of 42 adult therapy-related myelodysplastic syndromes (tMDS) patients treated at Memorial Sloan-Kettering Cancer Center and in 2 industry-sponsored decitabine trials (D0007 and DACO-020). The overall response rate (complete remission. +. marrow CR. +. hematologic improvement) was 38%, including 6 patients with complete remission (14%), 6 with marrow CR with or without hematologic improvement (14%), and 4 with hematologic improvement alone (10%). We conclude that DNA methyltransferase inhibitors showed activity in tMDS that is roughly comparable to that seen in de novo MDS.

AB - We retrospectively assessed morphologic and cytogenetic responses to 5-azacytidine and decitabine in a cohort of 42 adult therapy-related myelodysplastic syndromes (tMDS) patients treated at Memorial Sloan-Kettering Cancer Center and in 2 industry-sponsored decitabine trials (D0007 and DACO-020). The overall response rate (complete remission. +. marrow CR. +. hematologic improvement) was 38%, including 6 patients with complete remission (14%), 6 with marrow CR with or without hematologic improvement (14%), and 4 with hematologic improvement alone (10%). We conclude that DNA methyltransferase inhibitors showed activity in tMDS that is roughly comparable to that seen in de novo MDS.

KW - 5-Azacytidine

KW - Decitabine

KW - Leukemia

KW - Therapy-related cancer

UR - http://www.scopus.com/inward/record.url?scp=84864008372&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84864008372&partnerID=8YFLogxK

U2 - 10.1016/j.leukres.2012.04.025

DO - 10.1016/j.leukres.2012.04.025

M3 - Article

C2 - 22608310

AN - SCOPUS:84864008372

VL - 36

SP - 1093

EP - 1097

JO - Leukemia Research

JF - Leukemia Research

SN - 0145-2126

IS - 9

ER -